Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
Portfolio Pulse from Vandana Singh
Intellia Therapeutics announced updated interim results from the Phase 1 portion of the ongoing Phase 1/2 study of NTLA-2002, a CRISPR candidate for hereditary angioedema (HAE). A single dose led to a 95% mean reduction in monthly HAE attack rate. William Blair reiterates its Outperform rating, stating the data supports a competitive profile relative to peers like Ionis Pharmaceuticals' donidalorsen.
June 12, 2023 | 6:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intellia's NTLA-2002 shows promising results in Phase 1 study for HAE treatment, with a 95% mean reduction in attack rate. William Blair reiterates Outperform rating.
The positive interim results from the Phase 1 study of NTLA-2002 indicate a strong efficacy profile for the treatment of HAE. This, combined with William Blair's reiteration of its Outperform rating, is likely to have a positive short-term impact on Intellia's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Intellia's NTLA-2002 shows a competitive profile relative to peers like Ionis Pharmaceuticals' donidalorsen, according to William Blair.
While the news highlights the competitive profile of Intellia's NTLA-2002 relative to Ionis Pharmaceuticals' donidalorsen, it does not directly indicate any negative or positive impact on Ionis' stock price in the short term.
CONFIDENCE 80
IMPORTANCE 40
RELEVANCE 50